Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
0.00%
+0.49%
+0.94%
-2.97%
-1.83%
EBS
Emergent Biosolution
$6.31
Chart
$6.36 (-0.79%)
$4.66 (+35.41%)
$4.66 (+35.41%)
$7.93 (-20.43%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
0.00%
+0.49%
+0.94%
-2.97%
-1.83%
EBS
Emergent Biosolution
Current Price
$6.31
Login to view Emergent Biosolution (EBS) recommendation from the last 90 days from financial news and social media.
Chart
$6.36 (-0.79%)
$4.66 (+35.41%)
$4.66 (+35.41%)
$7.93 (-20.43%)
EBS Latest Analysis
Global Antidote Market to Cross the USD 4 Billion Mark by 2032 | DelveInsight. Global Antidote Market to Cross the USD 4 Billion Mark by 2032 |. DelveInsightThe antidote market is witnessing substantial growth largely propelled by the growing incidence of poisoning drug overdoses and snake or animal bites. This rising demand is supported by greater public health awareness government efforts to combat drug overdoses and continuous progress in product innovation. Moreover strategic product lau
Thu Jun 5, 2025
Emergent BioSolutions Partners with Victorias Voice Foundation for National Naloxone Awareness Day Initiative to Combat Opioid Overdose Deaths. Emergent BioSolutions and Victoria&rsquo.s Voice Foundation launch a campaign to promote naloxone awareness and reduce opioid overdose deaths.
Thu Jun 5, 2025
Emergent BioSolutions Supports Victorias Voice Foundations National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies. GAITHERSBURG Md. June 05 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) is teaming up with Victorias Voice Foundation to rally Americans to help save lives from the opioid epidemic on which honors the late Victoria Siegel and others who have succumbed to overdose. As part of the effort Victorias Voice has laun
Thu Jun 5, 2025
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial. ) released data from its Phase 1 trials of SION-719 and SION-451 the company’.s first-in-class nucleotide-binding domain 1 (NBD1) stabilizers .One hundred subjects were dosed in the SION-719 trial and 110 subjects were dosed in .Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna’.s preclinical cyst
Wed Jun 4, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
